Sodyum Glukoz Ko-Transporter 2 İnhibitörleri ve Böbrek Koruyucu Etkileri
Özet
Sodyum glukoz ko-transporter 2 (SGLT-2) inhibitörleri, tip 2 diyabet hastalarında glisemik kontrol sağlamak amacıyla geliştirilmiş oral antidiyabetik ilaçlar olup, günümüzde belirgin kardiyovasküler ve böbrek koruyucu etkileriyle ön plana çıkmaktadır. Kronik böbrek hastalığı (KBH) progresyonunu yavaşlatmada geleneksel olarak renin anjiotensin aldosteron sistemi (RAAS) inhibitörleri kullanılsa da, bu tedaviler KBH ilerlemesini tam olarak durduramamaktadır. EMPA-REG OUTCOME, CANVAS, CREDENCE ve DAPA-CKD gibi büyük ölçekli faz 3 klinik çalışmalar ve gerçek yaşam verileri; empagliflozin, dapagliflozin ve kanagliflozin gibi SGLT-2 inhibitörlerinin glukoz düşürücü etkilerinden bağımsız olarak, hem diyabetik hem de diyabetik olmayan KBH hastalarında tahmini glomerül filtrasyon hızı (tGFH) düşüşünü yavaşlattığını, albüminüri progresyonunu azalttığını, son dönem böbrek hastalığı (SDBH) ve akut böbrek hasarı (ABH) riskini önemli ölçüde düşürdüğünü kanıtlamıştır. Bu çoklu koruyucu etkilerin arkasındaki temel patofizyolojik mekanizmalar; proksimal tübüllerde sodyum ve glukoz geri emilimini inhibe ederek makula densaya ulaşan sodyumu artırmak ve tubüloglomerüler geribildirim yoluyla glomerüler hiperfiltrasyonu ile intrarenal basıncı azaltmaktır. Ayrıca sistemik kan basıncını düşürme, kilo kaybı sağlama, proinflamatuar (NF-κB, IL-6) ve profibrotik yolakları baskılama, oksidatif stresi azaltma, mitokondriyal bütünlüğü koruma ve eritropoetin (EPO) sentezini uyararak hematokriti artırma gibi ek mekanizmalar da sürece katkı sunar. Tedavi başlangıcında tGFH'de işlevsel, geri dönüşümlü akut bir düşüş görülse de bu durum pozitif hemodinamik etkinin kanıtı olup uzun vadeli fayda ile ilişkilidir. Genital mikotik enfeksiyonlar ve nadiren diyabetik ketoasidoz gibi riskleri bulunsa da, hastaların uygun eğitimi ve takibi ile SGLT-2 inhibitörleri kılavuzlarda KBH yönetiminin temel taşlarından biri haline gelmiştir.
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, initially developed as oral antidiabetic agents to achieve glycemic control in type 2 diabetes, have prominently emerged for their significant cardiovascular and renoprotective benefits. While renin-angiotensin-aldosterone system (RAAS) inhibitors are traditionally utilized to slow the progression of chronic kidney disease (CKD), they cannot completely eliminate the development or progression of renal decline. Major large-scale clinical trials and real-world studies, such as EMPA-REG OUTCOME, CANVAS, CREDENCE, and DAPA-CKD, have clearly demonstrated that SGLT-2 inhibitors like empagliflozin, dapagliflozin, and canagliflozin significantly slow the decline of the estimated glomerular filtration rate (eGFR), reduce progression to macroalbuminuria, and substantially lower the risk of end-stage kidney disease (ESKD) and acute kidney injury (AKI) in both diabetic and non-diabetic CKD patient populations, independent of their primary glucose-lowering effects. The primary underlying physiological mechanisms of this comprehensive renoprotection involve the inhibition of sodium and glucose reabsorption in the proximal tubules, which increases sodium delivery to the macula densa and restores tubuloglomerular feedback, thereby successfully reducing glomerular hyperfiltration and intrarenal pressure. Furthermore, additional renal and extra-renal pathways contribute to this process, including lowering systemic blood pressure, promoting weight loss, suppressing pro-inflammatory (NF-κB, IL-6) and pro-fibrotic signaling, mitigating oxidative stress, preserving mitochondrial dynamic integrity, and enhancing hematocrit levels by stimulating erythropoietin (EPO) production. Although these therapeutic agents typically induce a functional, fully reversible acute dip in eGFR upon initial treatment, this response serves as direct evidence of positive hemodynamic changes associated with long-term renal stabilization. Despite carrying manageable risks such as genital mycotic infections and rare instances of diabetic ketoacidosis, proper patient education and monitoring have firmly established SGLT-2 inhibitors as an essential cornerstone in modern nephrology guidelines for CKD management.
Referanslar
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1): 1–150.
Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. The Lancet. 2016;388(10041):276-284. doi: 10.1016/S0140-6736(16)30508-6.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International Supplements. 2020;98(4):S1-S115. doi: 10.1016/j.kint.2020.06.019.
Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. Kaiser Permanente Northern California CKD Outcomes Study. BMC Nephrology. 2018;19(1):146. doi: 10.1186/s12882-018-0942-1.
Provenzano M, Coppolino G, Faga T, et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Reviews in Cardiovascular Medicine. 2019;20(4):209-220. doi: 10.31083/j.rcm.2019.04.548.
Vijay K, Neuen BL, Lerma EV. Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. Cardiorenal Medicine. 2022;12(1):1-10. doi: 10.1159/000520909.
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD Chronic Kidney Disease Collaboration. The Lancet. 2020;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3
Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrology Dialysis Transplantation. 2011;26(6):1862-1871. doi: 10.1093/ndt/gfq656.
Toth-Manikowski S, Atta MG. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. Journal of Diabetes Research. 2015;2015:697010. doi: 10.1155/2015/697010.
Tangri N. Development and Progression of Chronic Kidney Disease. In: Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Rifkin DE. (eds.) National Kidney Foundation Primer on Kidney Diseases. 8nd Ed. Philadelphia: Elsevier Inc; 2023. 472-482.
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7.
Draznin B, Aroda VR, Bakris G, et al. American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
Fralick M, Colacci M, Odutayo A, et al. Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis. Journal of Diabetes and Its Complications. 2020;34(11):107704. doi: 10.1016/j.jdiacomp.2020.107704.
Shepard BD, Ecelbarger CM. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in Nephrology. 2021;41(4):331-348. doi: 10.1016/j.semnephrol.2021.06.005.
Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;12:3427-3434. doi: 10.2337/diabetes.54.12.3427.
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-225. doi: 10.1007/s00125-016-4157-3.
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology. 2017;13(1):11-26. doi: 10.1038/nrneph.2016.170.
Dubrofsky L, Cherney DZ, Bjornstad P. Pathogenesis, Pathophysiology, and Treatment of Diabetic Kidney Disease. In: Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Rifkin DE. (eds.) National Kidney Foundation Primer on Kidney Diseases. 8nd Ed. Philadelphia: Elsevier Inc; 2023. 255-271.
Giorgino F, Vora J, Fenici P, et al. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology. 2020;19(1):196. doi: 10.1186/s12933-020-01163-9.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. The New England Journal of Medicine. 2016;375(4):323-334. doi: 10.1056/NEJMoa1515920.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of Medicine. 2017;377(7):644-657. doi: 10.1056/NEJMoa1611925.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine. 2019;380(24):2295-2306. doi: 10.1056/NEJMoa1811744.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2019;380(4):347-357. doi: 10.1056/NEJMoa1812389.
Raz I, Wiviott SD, Yanuv I, et al. Effects of dapagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes: a predefined analysis from the DECLARE-TIMI 58 randomised, placebo-controlled trial.In: American Diabetes Association 79th Scientific Sessions; 7-11 June 2019, San Francisco, CA, USA. Oral Presentation 244-OR.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020;383(15):1436-1446. doi: 10.1056/NEJMoa2024816.
Wheeler DC, Stefansson BV, Batiushin M, et al. The dapaglifozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation. 2020;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. The New England Journal of Medicine. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190.
Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation. 2021;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685.
EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation. 2022;37(7):1317-1329. doi: 10.1093/ndt/gfac040.
Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. The Lancet Diabetes Endocrinology. 2020;8(1):27-35. doi: 10.1016/S2213-8587(19)30384-5.
Cahn A, Melzer-Cohen C, Pollack R, et al. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis. Diabetes, Obesity and Metabolism. 2019;21(2):340-348. doi: 10.1111/dom.13532.
Sugiyama S, Jinnouchi H, Yoshida A, et al. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. Journal of Clinical Medicine Research. 2019;11(4):267-274. doi: 10.14740/jocmr3761.
Fadini GP, Solini A, Manca ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes, Obesity and Metabolism. 2019;21(2):252-260. doi: 10.1111/dom.13508.
Pessoa TD, Campos LC, Carraro-Lacroix L, et al. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. Journal of The American Society of Nephrology. 2014;25(9):2028-39. doi: 10.1681/ASN.2013060588.
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887.
Schork A, Saynisch J, Vosseler A, Jaghutriz BA, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovascular Diabetology. 2019;18(1):46. doi: 10.1186/s12933-019-0852-y.
Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, Obesity and Metabolism. 2018;20(3):479-487. doi: 10.1111/dom.13126.
Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. Journal of The American Society of Nephrology. 1999;10(12):2569-2576. doi: 10.1681/ASN.V10122569.
Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2012;302(1):R75-83. doi: 10.1152/ajpregu.00357.2011.
Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-597. doi: 10.1161/CIRCULATIONAHA.113.005081.
Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2015;17(12):1180-1193. doi: 10.1111/dom.12572.
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy. 2016;17(12):1581-1583. doi: 10.1080/14656566.2016.1201073.
Bosch A, Ott C, Jung S, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovascular Diabetology. 2019;18(1):44. doi: 10.1186/s12933-019-0839-8.
Adam CA, Anghel R, Marcu DTM, et al. Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review). Life (Basel). 2022;12(6):803. doi: 10.3390/life12060803.
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC: Basic to Translational Science. 2020;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004.
Kawanami D, Matoba K, Takeda Y, et al. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences. 2017;18(5):1083. doi: 10.3390/ijms18051083.
Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. American Journal of Physiology Renal Physiology. 2014;306(2):F194-204. doi: 10.1152/ajprenal.00520.2013.
Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Hormone and Metabolic Research. 2015;47(9):686-692. doi: 10.1055/s-0034-1395609.
Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442. doi: 10.1371/journal.pone.0054442.
Kojima N, Williams JM, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. The Journal of Pharmacology and Experimental Therapeutics. 2013;345(3):464-472. doi: 10.1124/jpet.113.203869.
Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777. doi: 10.1371/journal.pone.0100777.
Hatanaka T, Ogawa D, Tachibana H, et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacology Research & Perspectives. 2016;4(4):e00239. doi: 10.1002/prp2.239.
Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. The British Journal of Pharmacology. 2013;170(3):519-531. doi: 10.1111/bph.12269.
Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. The Journal of Biological Chemistry. 2017;292(13):5335-5348. doi: 10.1074/jbc.M117.779520.
Llorens-Cebrià C, Molina-Van den Bosch M, Vergara A, et al. Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules. 2022;12(1):143. doi: 10.3390/biom12010143.
Mima A. Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022;8(2):e08878. doi: 10.1016/j.heliyon.2022.e08878.
Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nature Genetics. 2000;26(2):211-215. doi: 10.1038/79944.
Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nature Reviews Nephrology. 2017;13(10):629-646. doi: 10.1038/nrneph.2017.107.
Delettre C, Lenaers G, Griffoin JM, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nature Genetics. 2000;26(2):207-210. doi: 10.1038/79936.
Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. The American Journal of Physiology-Renal Physiology. 2019;317(4):F767-F780. doi: 10.1152/ajprenal.00565.2018.
Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006;125(7):1241-1252. doi: 10.1016/j.cell.2006.06.010.
Takagi S, Li J, Takagaki Y, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. Journal of Diabetes Investigation. 2018;9(5):1025-1032. doi: 10.1111/jdi.12802.
Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2017;8(4):416-427. doi: 10.1111/jdi.12644.
Tomita I, Kume S, Sugahara S, et al. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metabolism. 2020;32(3):404-419.e6. doi: 10.1016/j.cmet.2020.06.020.
Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Therapy. 2014;5(2):355-366. doi: 10.1007/s13300-014-0089-4.
Cai X, Yang W, Gao X, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018;26(1):70-80. doi: 10.1002/oby.22066.
Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Journal of Endocrinology and Metabolism. 2012;97(3):1020-1031. doi: 10.1210/jc.2011-2260.
Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(9):1654-1659. doi: 10.1161/ATVBAHA.108.170316.
Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008;117(5):605-613. doi: 10.1161/CIRCULATIONAHA.107.743062.
Mulyadi L, Stevens C, Munro S, et al. Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Annals of Nutrition and Metabolism. 2001;45(2):67-71. doi: 10.1159/000046708.
Lytvyn Y, Škrtić M, Yang GK, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. American Journal of Physiology Renal Physiology. 2015;308(2):F77-83. doi: 10.1152/ajprenal.00555.2014.
Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharmaceutics&Drug Disposition. 2014;35(7):391-404. doi: 10.1002/bdd.1909.
Sano M, Goto S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation. 2019;139(17):1985-1987. doi: 10.1161/CIRCULATIONAHA.118.038881.
Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. 2013;15(9):853-862. doi: 10.1111/dom.12127
O'Neill J, Fasching A, Pihl L, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. American Journal of Physiology Renal Physiology. 2015;309(3):F227-234. doi: 10.1152/ajprenal.00689.2014.
Takaori K, Nakamura J, Yamamoto S, et al. Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis. Journal of The American Society of Nephrology. 2016;27(8):2393-2406. doi: 10.1681/ASN.2015060647.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062.
Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports. 2022;7(7):1463-1476. doi: 10.1016/j.ekir.2022.04.094.
Lega IC, Bronskill SE, Campitelli MA, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obesity and Metabolism. 2019;21(11):2394-2404. doi: 10.1111/dom.13820.
Thong KY, Yadagiri M, Barnes DJ, et al; ABCD Nationwide Dapagliflozin Audit contributors. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Primary Care Diabetes. 2018;12(1):45-50. doi: 10.1016/j.pcd.2017.06.004.
Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Annals of Pharmacotherapy. 2021;55(4):543-548. doi: 10.1177/1060028020951928.
Silverii GA, Dicembrini I, Monami M, et al. Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obesity and Metabolism. 2020;22(2):272-275. doi: 10.1111/dom.13900.
Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Research and Clinical Practice. 2014;103(3):373-81. doi: 10.1016/j.diabres.2013.12.052.
Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and Its Complications. 2015;29(8):1295-1303. doi: 10.1016/j.jdiacomp.2015.07.011.
Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obesity and Metabolism. 2018;20(11):2585-2597. doi: 10.1111/dom.13424.
Erythropoulou-Kaltsidou A, Polychronopoulos G, Tziomalos K. Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk. Diabetes Therapy. 2020;11(1):7-14. doi: 10.1007/s13300-019-00724-w.
Dandona P, Mathieu C, Phillip M, et al; DEPICT-1 Investigators. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018;41(12):2552-2559. doi: 10.2337/dc18-1087.
Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. The Clinical Journal of the American Society of Nephrology. 2021;16(8):1284-1291. doi: 10.2215/CJN.17621120.
Heerspink HJL, Cherney DZI. Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. The Clinical Journal of the American Society of Nephrology. 2021;16(8):1278-1280. doi: 10.2215/CJN.02480221.
Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2019;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6.
Sridhar VS, Tuttle KR, Cherney DZI. We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury. The American Journal of Kidney Diseases. 2020;76(4):454-456. doi: 10.1053/j.ajkd.2020.05.014.
Verma A, Patel AB, Waikar SS. SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure. Cell Metabolism. 2020;32(1):13-14. doi: 10.1016/j.cmet.2020.06.014.
Mahling M, Schork A, Nadalin S, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus. Kidney and Blood Pressure Research. 2019;44(5):984-992. doi: 10.1159/000501854.
Hecking M, Jenssen T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nature Reviews Nephrology. 2019;15(9):525-526. doi: 10.1038/s41581-019-0173-0.
